| Literature DB >> 31882007 |
Franco Toscani1, Silvia Finetti1, Fabrizio Giunco2, Ines Basso3, Debora Rosa4, Francesca Pettenati1, Alessandro Bussotti5, Daniele Villani6, Simona Gentile7, Lorenzo Boncinelli8, Massimo Monti9, Sandro Spinsanti10, Massimo Piazza11, Lorena Charrier12, Paola Di Giulio13,14.
Abstract
BACKGROUND: Barriers to palliative care still exist in long-term care settings for older people, which can mean that people with advanced dementia may not receive of adequate palliative care in the last days of their life; instead, they may be exposed to aggressive and/or inappropriate treatments. The aim of this multicentre study was to assess the clinical interventions and care at end of life in a cohort of nursing home (NH) residents with advanced dementia in a large Italian region.Entities:
Keywords: Dementia; Nursing homes; Palliative care
Mesh:
Year: 2019 PMID: 31882007 PMCID: PMC6935223 DOI: 10.1186/s12904-019-0510-x
Source DB: PubMed Journal: BMC Palliat Care ISSN: 1472-684X Impact factor: 3.234
Main characteristics of the 482 nursing home (NH) residents with advanced dementia (Functional Assessment Staging Tool stage ≥7c)
| n ( | % | 95% CIb (%) | |
|---|---|---|---|
| Sex Female | 365 | 75.7 | 71.9;79.5 |
| Age at NH admission, years, median (IQRb): 84.1 (79–88.7) | |||
| Diagnosis of dementia | |||
| Alzheimer | 129 | 26.8 | 22.8;30.7 |
| Not defined | 175 | 36.3 | 32.0;40.6 |
| Vascular | 138 | 28.6 | 24.6;32.7 |
| Mixed | 33 | 6.8 | 4.6;9.1 |
| Lewy body | 7 | 1.5 | 0.4;2.5 |
| Comorbidities | |||
| Genitourinary | 435 | 90.2 | 87.6;92.9 |
| Musculoskeletal | 409 | 84.9 | 81.6;88.0 |
| Gastrointestinal tract | 135 | 28.0 | 24.0;32.0 |
| Peripheral and central nervous system | 314 | 65.1 | 60.9;69.4 |
| Hypertension | 238 | 49.4 | 44.9;53.8 |
| Cardiovascular | 237 | 49.2 | 44.7;53.6 |
| Head and neck | 207 | 42.9 | 38.5;47.4 |
| Vascular | 195 | 40.5 | 36.1;44.8 |
| Respiratory | 100 | 20.7 | 17.2;24.4 |
| Endocrine-metabolic | 135 | 28.0 | 24.0;32.0 |
| Kidney | 55 | 11.4 | 8.6;14.2 |
| Liver | 30 | 6.2 | 4.1;8.4 |
| Othersa | 18 | 3.7 | 2.0;5.4 |
aOthers: other cancers [15]; anemia [2]; pressure sores [1]
bCI Confidence interval, IQR Interquartile range
Nutrition and hydration in the 7 days before death
| n ( | % | 95% CIa (%) | |
|---|---|---|---|
| IVa hydration (alone or supplement) | 227 | 48.4 | 43.9;52.9 |
| Nutrition/hydration by mouth only | 94 | 20.0 | 16.4;23.7 |
| SFAa only (or SFA+ mouth) | 70 | 14.9 | 11.7;18.1 |
| Tube feeding | 63 | 13.4 | 10.3;16.5 |
| Parenteral Nutrition | 15 | 3.2 | 1.6;4.8 |
| Comfort hydration (IV and SFA) | 99/455 | 21.8 | 18.0;25.5 |
aCI Confidence interval, IV Intravenous, SFA Subcutaneous fluids administration
b13 residents with missing information on nutrition and hydration
Invasive treatments/interventions in the 7 days before death
| n ( | % | 95% CIb (%) | |
|---|---|---|---|
| Oral/tracheal suctioning | 101 | 21.0 | 17.3;24.6 |
| Blood collection | 73 | 15.1 | 11.9;18.3 |
| Peripheral vein cannulation (one or more attempts) | 53 | 11.0 | 8.2;13.8 |
| Insertion/repositioning of urinary catheter | 30 | 6.2 | 4.1;8.4 |
| Insertion/repositioning of a nasogastric tube (2 PEGsb) | 11 | 2.3 | 0.9;3.6 |
| Insertion of a central venous catheter | 3 | 0.6 | 0.0;1.3 |
| Other invasive treatmentsa | 6 | 1.2 | 0.2;2.2 |
aOther treatments (residents could be exposed to more than one treatment): Enema [2]; Glycaemia measurement [2]; Hemogasanalysis [1]; Flu vaccine [1]
bCI Confidence interval, PEG Percutaneous endoscopic gastrostomy
Prescriptions in the 7 days before death classified according to the Anatomical Therapeutic Chemical (ATC) code
| ATC code | n ( | % | 95% CIb (%) | |
|---|---|---|---|---|
| Anticoagulants - Antiplatelets | B01A | 166 | 52.5 | 47.0;58.0 |
| Drugs for acid related disorders | A02 | 153 | 48.4 | 42.9;53.9 |
| Cardiovascular System | C | |||
| Cardiac therapy | C01A, C01D | 130 | 41.1 | 35.7;46.6 |
| Beta blocking agents | C07 | 31 | 9.8 | 6.5;13.1 |
| Anti-arrhythmic class I-III | C01B | 8 | 2.5 | 0.8;4.2 |
| Antibiotics (antibacterial/antimycotics) | J01;J02 | 107 | 33.9 | 28.6;39.1 |
| Diuretics | C03 | 110 | 34.8 | 29.5;40.1 |
| Opioids | N02A | 108 | 34.2 | 28.9;39.4 |
| Laxatives | A06 | 96 | 30.4 | 25.3;35.4 |
| Vitamins and mineral supplements | A11; A12 | 88 | 27.8 | 22.9;32.8 |
| Antipsychotics | N05A | 79 | 25.0 | 20.2;29.8 |
| Benzodiazepine derivates | N05CD | 70 | 22.2 | 17.6;26.7 |
| Steroids | H02AB | 58 | 18.4 | 14.1;22.6 |
| Drugs for the respiratory system | R | 37 | 11.7 | 8.2;15.2 |
| Antiepileptics | N03 | 30 | 9.5 | 6.3;12.7 |
| Insulin and other glucose lowering | A10 | 27 | 8.5 | 5.5;11.6 |
| Acetaminophen | N02B | 24 | 7.6 | 4.7;10.5 |
| Antidepressants | N06 | 24 | 7.6 | 4.7;10.5 |
| Anti-parkinson | N04 | 23 | 7.3 | 4.4;10.1 |
| Antiemetics | A04 | 19 | 6.0 | 3.4;8.6 |
| Hyoscine Butylbromide | N07 | 14 | 4.4 | 2.2;6.7 |
| Thyroid drugs | H03 | 17 | 5.4 | 2.9;7.9 |
| Othersa | 29 | 9.2 | 6.0;12.4 |
aOthers: Allopurinol (M04 11), Drugs for benign prostatic hypertrophy (Tamlusosin, Finasteride (G04 AC, 10), Antidiarrhoics (A07, 5), Ursodesooxyicholic acid (A05AA02 4), Drugs for treatment of hyperkaliemia and hyperphosphatemia (V03AE, 3), Hormone antagonists (L02, 2), Baclofen (M03BX, 2); only 1: Epoietine (B03); Rociverine (A03AA)
bCI Confidence interval